Perspective Therapeutics, Inc. (CATX): M&A transaction — Perspective Therapeutics closes sale of Isoray Cesium-131 business for stock and royalties

Perspective Therapeutics, Inc.

Sale closed April 12, 2024; Isoray receives 279,516 GT Medical shares (0.5% fully diluted, 0.44% if C-1 warrants exercised) and 4-year tiered royalties.
Royalty on Cesium-131 seed ex-GammaTile: 3% (≤$10M annual net sales), 4% ($10-15M), 5% (≥$15M); GammaTile royalty: 0.5%.
Pro forma 2023 continuing ops: revenue $1.5M, net loss $37.0M (vs reported $46.5M net loss including discontinued ops).
Discontinued Isoray ops 2023: net sales $6.9M, net loss $4.9M plus $4.17M loss on classification as held for sale.
Pro forma balance sheet: total assets $92.8M, stockholders' equity $75.2M after removing Isoray assets/liabilities.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

Perspective Therapeutics, Inc. completed a disposition involving GT Medical Technologies, Inc. for 279,516 shares of GT Medical common stock and certain cash royalty payments for four years based on net sales (closed 2024-04-12).

Action: disposition
Counterparty: GT Medical Technologies, Inc.
Consideration: 279,516 shares of GT Medical common stock and certain cash royalty payments for four years based on net sales
Closing: 2024-04-12

Exact text from the filing

the liabilities of Isoray. Pursuant to the terms of, and subject to the conditions specified in, the Asset Purchase Agreement, at the Closing, (i) GT Medical issued to Isoray 279,516 shares of GT Medical’s common stock, par value $0.0001 per share, representing 0.5% of GT Medical’s issued and outstanding capital stock on a fully diluted basis as of the

View on SEC.gov

27 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-044769

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.